Christensen, Rasmus M <br/><br/>
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.  [electronic resource] 

 -  Drug safety  08 2019 
 - 957-971 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1179-1942 
<br/><br/><label>Standard No.: </label>10.1007/s40264-019-00812-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Glucagon-Like Peptides--adverse effects<br/>Humans<br/>Hypoglycemic Agents<br/>Liraglutide--adverse effects<br/>Obesity--drug therapy<br/>Randomized Controlled Trials as Topic<br/>Risk Assessment<br/>Glucagon-Like Peptide-1 Receptor Agonists